 | | Vol. 14.28 – 28 July, 2023 |
| |
|
|
| To determine the significance of 3′ untranslated region (3′ UTR) mutations in disease, investigators identified 3′ UTR somatic variants across 185 advanced prostate tumors, discovering 14,497 single-nucleotide mutations enriched in oncogenic pathways and 3′ UTR regulatory elements.
[Cell Reports] |
|  |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| A phenotypic screen was performed to identify novel inhibitors of chemoresistant prostate cancer (PCa) cells. The mechanism of action of potential candidate(s) was investigated using in silico docking, and molecular and cellular assays in chemoresistant PCa cells.
[British Journal of Cancer] |
|
|
|
| Investigators performed a retrospective cohort study including 165 men with grade group 2-4 prostate cancer who underwent radical prostatectomy (RP) at a single academic institution and Decipher testing of the RP specimen.
[European Urology Oncology] |
|
|
|
| Researchers showed that S-phase kinase-associated protein 2 catalyzed K6- and K29-linked polyubiquitination of forkhead box protein A1 (FOXA1) for lysosomal-dependent degradation.
[Molecular Oncology] |
|
|
|
| Scientists investigated the antitumor effects of compound MPC309, a trivalent display of ethisterone conjugated to a peptoid oligomer backbone that binds to the androgen receptor with nanomolar affinity. MPC309 exhibited potent antiproliferative effects on various enzalutamide-resistant prostate cancer models.
[Molecular Cancer Therapeutics] |
|
|
|
| Investigators focused on the function of upstream-stimulating factor 1 (USF1) in glycolysis and the malignant development of prostate adenocarcinoma (PRAD). Bioinformatics predictions suggested that USF1 was poorly expressed in PRAD.
[Molecular Carcinogenesis] |
|
|
|
| Western blotting and immunofluorescence were performed to compare programmed necrosis ligand 1 (PD-L1) levels in exosomes derived from different prostate cancer cells.
[Cancer Medicine] |
|
|
|
| Scientists investigated the levels of EZH2 and the altered pathways in public database which was comprised with primary and metastatic prostate cancer patient tumors.
[The Prostate] |
|
|
|
| Researchers reported the antiproliferative potential of 3,5,7-trihydroxyflavone in prostate cancer cell line via reactive oxygen species-mediated cascades and examined the tumor reduction potential in swiss albino mice.
[Journal of Biochemical and Molecular Toxicology] |
|
|
|
| The authors examined whether circulating tumor cells (CTCs) identified patients with altered p300/CBP acetylation. CTCs were isolated from 13 advanced prostate cancer patients using Exclusion-based Sample Preparation technology.
[Oncotarget] |
|
|
|
|
| Studies present mechanistic evidence of how the host microbiota might be implicated in prostate carcinogenesis and tumor progression.
[Nature Reviews Urology] |
|
|
|
|
| Five rising junior investigators were awarded a total of $1.32 million from Alabama State University’s (ASU) Cancer Biology Research and Training program to build cancer research capacity at ASU.
[Alabama State University] |
|
|
|
|
| September 20 – 23, 2023
Milan, Italy |
|
|
|
|
|
| | Debiopharm – Lausanne, Switzerland |
|
|
|
| | IRB Barcelona – Barcelona, Spain |
|
|
|
| | Washington University – St. Louis, Missouri, United States |
|
|
|
| | Albert Einstein College of Medicine – New York City, New York, United States |
|
|
|
| | University of Miami – Miami, Florida, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
